微信网页版

从生产到研发，外资企业拥抱中国“指数级”机遇,从生产到研发，外资企业拥抱中国“指数级”机遇_我的网站

一 |     Influenza and other respiratory viruses are starting to circulate but so far remain lower than this time last year, according to the Centers for Disease Control and Prevention.As of Oct. 7, CDC's FluView weekly report showed that the percent of flu cases were relatively unchanged, rising about 1% compared to the week prior.In that same timeframe, 1,127 people were hospitalized with influenza, up from 1,050 people the week prior. About 35% of all flu hospitalizations were reported in the southeast of the U.S., which experts say is a typical trend at the start of the flu season.Most of the flu cases detected were Influenza A and the most common subtype was Influenza A(H1N1), which is the strain of the virus that the flu vaccine usually offers better protection from, according to the CDC.The percent of all reported respiratory viruses circulating over the past week have been relatively unchanged nationally, but there is regional variability. Region 9 -- made up of Arizona, California, Hawaii, and Nevada -- was the only region that saw an increase.Still, the numbers in all regions of the U.S. remain below their baseline and outpatient respiratory illness activity is either minimal or low throughout most of the U.S., according to the CDC.Alaska is the only state that is currently experiencing moderate respiratory illness activity. Influenza typically circulates this time of year and peaks between December and February for most of the U.S., according to the CDC.Respiratory syncytial virus (RSV) numbers are on the rise and are projected to increase further, according to the CDC's weekly surveillance. RSV typically circulates from October to April, according to the CDC.

How to prepare for this year's cold and flu season

This time last year, the U.S. was bracing for a "tripledemic" amid rising cases of COVID-19, influenza and RSV after the seasons became more unpredictable during the COVID-19 pandemic.Dr. John Brownstein, chief innovation officer at Boston Children's Hospital and an ABC News contributor, said these early cases are behaving in a more predictable pattern."The data is pointing to something a little bit more par for the course. We're seeing the early rise of RSV and flu at a time when you'd expect it," Brownstein said.Brownstein, however, cautioned that cases of respiratory viruses are expected to increase further and higher levels still have potential to strain health systems and cause severe illnesses, Brownstein said."I think there's still concern around the threat of all three respiratory viruses plus, of course, the rest of the seasonal mix [of viral illnesses], wreaking havoc on our health systems," he said.Experts are hopeful that new and updated immunizations that protect against COVID-19, influenza and RSV will stave off the strain on health care systems.These viruses may only cause mild illness for many people, but young babies, pregnant women, people who are immunocompromised and the elderly are at highest risk for severe disease.Everyone 6 months and older is eligible for an updated COVID-19 shot and the annual flu vaccine.The Department of Health and Human Services told ABC News that, so far, more than 7 million updated COVID-19 shots have been administered. The CDC recommends getting the COVID-19 and flu vaccines by the end of October and encourages both to be given at the same time.Adults who are 60 years and older can get an RSV vaccine and pregnant women who are in their third trimester can get an RSV shot that provides protection against RSV to their baby for the first 6 months of life.Babies less than 8 months old who are born to mothers who did not get an RSV vaccine during pregnancy can get a protective shot called nirsevimab that offers about five months of protection against RSV.Nirsevimab is a one-dose shot made of monoclonal antibodies, which are proteins manufactured in a lab and mimic the antibodies the body naturally creates when fighting an infection. This is different than a vaccine, which activates the immune system.Brownstein said the pandemic has helped make many health systems better prepared for seasonal spikes in respiratory viruses and is hopeful that people are more motivated to stay up to date on shots that are available for protection and prevention this respiratory virus season."Now is really the time to get the protection advanced of the seasons really heating up," Brownstein said.Dr. Jade A Cobern, M.D., M.P.H, a licensed and practicing physician, is a member of the ABC News Medical Unit.。    　　商务部数据显示，今年前7个月，全国新设立外商投资企业37711家，同比增长4.4%，高技术产业实际使用外资1823.1亿元，同比增长32.7%。今年上半年，近4800家外资企业追加对华投资。

二 | 从“中国生产”到“中国研发”，外企在华角色正在发生一场深层转变。　　“中国的很多发展，将是指数级的。”外资企业负责人表示，市场、人才、政策三重优势叠加，以及“十五五”规划带来的新机遇，让更多外资选择与中国共创。　　69年前，德国企业蔡司来到中国。蔡司大中华区总裁兼首席执行官费铭远说，中国的角色变了三次：第一阶段是销售市场；第二阶段，中国形成了非常好的供应链，于是建立工厂、引入研发；现在第三阶段，是与中国合作创新——“不仅为中国市场创新，也为整个世界创新。”　　ABB机器人同样如此。

三 | “从2005年到现在，我们在中国已经有近300人的研发团队了。

四 | ”ABB机器人中国区总裁韩晨介绍，中国是ABB全球最大的机器人交付市场，中国研发中心与瑞典研发中心形成“双中心”。“小型机器人的全球研发中心、控制柜的研发中心，甚至一些领域的首席专家，都在中国。”　　今年以来，中国持续为外资企业向高端、新兴领域拓展提供政策支持：《鼓励外商投资产业目录(2025年版)》施行，引导更多外资投向先进制造业、现代服务业、高新技术、节能环保等领域；《利用外资固稳促优行动方案》出台，针对外资并购、数据跨境流动等热点关切，加力提升外商投资便利度。　　在上海做研发“比在瑞典速度更快、灵活性更强”，韩晨说，高校提供了从机械制造到人工智能的高端人才，政府的“工业上楼”政策和当地企业生态协同也提供了有力支持。　　费铭远说：“中国如今真的是领先的创新国家之一。

五 | 当我看到中国受教育的人的数量、大学毕业生的数量，以及大学的质量，正是像蔡司这样的公司需要紧密合作、协同创新的地方。

六 | ”　　未来5年，中国超大规模市场优势将持续彰显，科技创新、扩大内需、绿色转型、对外开放等重点部署，都将为全球产业界带来巨大发展机遇。展望“十五五”，韩晨表示，数据中心领域潜力巨大。费铭远用一句话概括他对中国市场的判断：“人类总是倾向于线性思维，但中国很多发展将是指数级的——从1到2到4到8……能参与这个过程，会非常有意思。

Current article:http://www.zongchaeiwengshuabaisisuofu.sbs/mbi4tc0/xakjs.ppt

Published on:00:33:27